10 Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

11 Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

12 Monovalent Rotavirus Vaccine Effectiveness and Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data From the First 3 Years After Introduction

13 Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

14 Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study

15 Pneumococcal vaccines WHO position paper - 2012 - recommendations

16 Effects of vaccination on invasive pneumococcal disease in South Africa

17 The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants

18 Population Impact and Effectiveness of Monovalent Rotavirus Vaccination in Urban Malawian Children 3 Years After Vaccine Introduction: Ecological and Case-Control Analyses

19 Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine

20 Impact of Rotavirus Vaccine Introduction and Postintroduction Etiology of Diarrhea Requiring Hospital Admission in Haydom, Tanzania, a Rural African Setting

21 Use of Patients With Diarrhea Who Test Negative for Rotavirus as Controls to Estimate Rotavirus Vaccine Effectiveness Through Case-Control Studies

22 Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh

23 Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

24 Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

25 Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

26 Effectiveness of Monovalent Rotavirus Vaccine After Programmatic Implementation in Botswana: A Multisite Prospective Case-Control Study

27 An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

28 Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine

29 Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial

30 Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant

31 A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia

32 Immunization against measles in children at risk for severe disease

33 Effect of Condoms on Reducing the Transmission of Herpes Simplex Virus Type 2 From Men to Women

34 Response to live attenuated measles vaccine in children with severe kwashiorkor

35 Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

36 Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine

37 Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

38 Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination

39 subcloning and assessment of the expression of synthetic botulinum neurotoxin type b binding domain (bd/b)

40 dna vaccine: the third generation vaccine

41 Pneumococcal coinfection with human metapneumovirus

42 High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model

43 Current situation and future prospects of Echinococcus granulosus vaccine candidates: A systematic review

44 Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

45 Induction of specific T-cell responses in HIV infection

46 Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults

47 ChemInform Abstract: Total Synthesis of Baccatin III and Taxol

48 CONTENT REVIEW OF VACCINES AND VACCINATION RELATED NEWS IN INTERNET NEWSPAPERS

49 Meningococcal conjugate vaccines: optimizing global impact

50 Review of oral cholera vaccines: efficacy in young children

51 CONTENT REVIEW OF VACCINES AND VACCINATION RELATED NEWS IN INTERNET NEWSPAPERS

52 CONTENT REVIEW OF VACCINES AND VACCINATION RELATED NEWS IN INTERNET NEWSPAPERS

53 Meningococcal conjugate vaccines: optimizing global impact

54 Review of oral cholera vaccines: efficacy in young children

55 Acceptability and Feasibility of Delivering Pentavalent Vaccines in a Compact, Prefilled, Autodisable Device in Vietnam and Senegal.

56 At the bench: Engineering the next generation of cancer vaccines.

57 "You need to do your research": Vaccines, contestable science, and maternal epistemology.

58 The art of partnerships for vaccines.

59 The costs of delivering vaccines in low- and middle-income countries: Findings from a systematic review.

60 A Scoping Review of Investment Cases for Vaccines and Immunization Programs.

61 A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus.

62 Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.

63 Current status and future prospects for the development of substance abuse vaccines.

64 Combined use of inactivated and oral poliovirus vaccines in refugee camps and surrounding communities - Kenya, December 2013.

65 Workshop report: Experimental animal models for universal influenza vaccines.

66 A comparative study of live attenuated F strain-derived Mycoplasma gallisepticum vaccines.

67 A combinatorial approach to the design of vaccines.

68 High performance of rapid influenza diagnostic test and variable effectiveness of influenza vaccines in Mexico.

69 Protective immunity against influenza virus challenge by norovirus P particle-M2e and HA2-AtCYN vaccines in chickens.

70 Procurement of Category 2 Vaccines in China.

71 Vacinas meningocócicas conjugadas: eficácia e novas combinações Meningococcal conjugate vaccines: efficacy and new combinations

72 Erratum: Recent mechanistic insights on glycoconjugate vaccines and future perspectives (ACS Chemical Biology (2013) 8 (1653-1663) DOI: 10.1021/cb400423g)

73 Comparison of serum and salivary antibodies in children vaccinated with oral live or parenteral inactivated poliovirus vaccines of different antigen concentrations.

74 Has the public lost confidence in vaccines because of a vaccine scandal in China.

75 A social justice perspective on access to human rabies vaccines

76 Erratum to: System immunology-based identification of blood transcriptional modules correlating to antibody responses in sheep (npj Vaccines, (2018), 3, 1, (41), 10.1038/s41541-018-0078-0)

77 Do health care providers trust product monograph information regarding use of vaccines in pregnancy? A qualitative study.

78 Perception of mandatory infant vaccines and trust in vaccination among first-year healthcare students: An opportunity window for the training of future healthcare workers.

79 Does improving maternal knowledge of vaccines impact infant immunization rates? A community-based randomized-controlled trial in Karachi, Pakistan

80 Monophosphoryl-Lipid A (MPLA) is an Efficacious Adjuvant for Inactivated Rabies Vaccines.

81 An overview of biodegradable nanomaterials and applications in vaccines.

82 Learning from epidemiological, clinical, and immunological studies on Mycobacterium africanum for improving current understanding of host–pathogen interactions, and for the development and evaluation of diagnostics, host-directed therapies, and vaccines for tuberculosis

83 Obstacles to developing vaccines for the Third World.

84 Evaluation of novel inactivated vaccines for the SAT 1, SAT 2 and SAT 3 serotypes of foot-and-mouth disease in pigs.

85 How Can the Typhoid Fever Surveillance in Africa and the Severe Typhoid Fever in Africa Programs Contribute to the Introduction of Typhoid Conjugate Vaccines?

86 The Severe Typhoid Fever in Africa Program Highlights the Need for Broad Deployment of Typhoid Conjugate Vaccines

87 Exploring the relationship between newspaper coverage of vaccines and childhood vaccination rates in Spain.

88 Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis.

89 Pharmacists' impact on older adults' access to vaccines in the United States.

90 Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain.

91 Safety and Impact on Training of the Influenza Vaccines in Elite Athletes Participating in the Rio 2016 Olympics.

92 Fighting flu: the importance of vaccines in rheumatic disease

93 Current challenges: from the path of “original antigenic sin” towards the development of universal flu vaccines: Flu vaccine efficacy encounters significant hurdles from pre-existing immunity of the host suggesting assessment of host immunity before vaccination

94 Searching for Improved Flu Vaccines-The Time Is Now

95 Antibiotics can impede flu vaccines

96 Frequently asked questions about flu vaccines: The IntoVac responses

97 Neutrinos, flu vaccines and Fukushima ruling

98 Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by instituto Butantan

99 Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil

100 Economical value of vaccines for the developing countries-the case of Instituto Butantan, a public institution in Brazil

101 Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Keyword Connections

Journals

Research Groups

Bibliographies